Stephen Willey
Stock Analyst at Stifel
(4.12)
# 460
Out of 5,241 analysts
134
Total ratings
46.46%
Success rate
16.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Hold | $44 → $47 | $48.67 | -3.43% | 21 | May 6, 2026 | |
| INCY Incyte | Maintains: Buy | $120 → $123 | $95.60 | +28.66% | 9 | Apr 29, 2026 | |
| CELC Celcuity | Maintains: Buy | $115 → $125 | $130.96 | -4.55% | 3 | Mar 26, 2026 | |
| INSM Insmed | Maintains: Buy | $205 → $208 | $107.41 | +93.65% | 9 | Mar 24, 2026 | |
| ZYME Zymeworks | Maintains: Buy | $40 → $47 | $24.40 | +92.62% | 8 | Mar 3, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $125 → $110 | $64.07 | +71.69% | 2 | Feb 17, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $33 → $35 | $15.24 | +129.66% | 6 | Jan 29, 2026 | |
| NKTX Nkarta | Maintains: Buy | $12 → $11 | $2.68 | +310.45% | 5 | Nov 11, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $30 → $9 | $3.64 | +147.25% | 3 | Aug 29, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $8 → $7 | $4.05 | +72.84% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $18.48 | +51.52% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $5 | $4.52 | +10.62% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $20 | $4.72 | +323.73% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $14.11 | +608.72% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.22 | +227.87% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $20.04 | +134.59% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $120 | $20.30 | +491.13% | 7 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $2.73 | +46.52% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $54.05 | +14.71% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.81 | +397.24% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.37 | +406.33% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $1.22 | +23,506.56% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $2.59 | +710.81% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $2.13 | +87.79% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $294.30 | -58.21% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $73.84 | -36.35% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $49.81 | +118.83% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $21.73 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $8.06 | +185.36% | 5 | Feb 7, 2018 |
Exelixis
May 6, 2026
Maintains: Hold
Price Target: $44 → $47
Current: $48.67
Upside: -3.43%
Incyte
Apr 29, 2026
Maintains: Buy
Price Target: $120 → $123
Current: $95.60
Upside: +28.66%
Celcuity
Mar 26, 2026
Maintains: Buy
Price Target: $115 → $125
Current: $130.96
Upside: -4.55%
Insmed
Mar 24, 2026
Maintains: Buy
Price Target: $205 → $208
Current: $107.41
Upside: +93.65%
Zymeworks
Mar 3, 2026
Maintains: Buy
Price Target: $40 → $47
Current: $24.40
Upside: +92.62%
Disc Medicine
Feb 17, 2026
Maintains: Buy
Price Target: $125 → $110
Current: $64.07
Upside: +71.69%
Nurix Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $35
Current: $15.24
Upside: +129.66%
Nkarta
Nov 11, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $2.68
Upside: +310.45%
X4 Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $30 → $9
Current: $3.64
Upside: +147.25%
AbCellera Biologics
Aug 8, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $4.05
Upside: +72.84%
Jun 25, 2025
Initiates: Buy
Price Target: $28
Current: $18.48
Upside: +51.52%
May 14, 2025
Maintains: Hold
Price Target: $6 → $5
Current: $4.52
Upside: +10.62%
May 13, 2025
Maintains: Hold
Price Target: $25 → $20
Current: $4.72
Upside: +323.73%
Mar 21, 2025
Maintains: Buy
Price Target: $240 → $100
Current: $14.11
Upside: +608.72%
Feb 27, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.22
Upside: +227.87%
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $20.04
Upside: +134.59%
Aug 20, 2024
Maintains: Buy
Price Target: $240 → $120
Current: $20.30
Upside: +491.13%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $2.73
Upside: +46.52%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $54.05
Upside: +14.71%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $1.81
Upside: +397.24%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $2.37
Upside: +406.33%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $1.22
Upside: +23,506.56%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $2.59
Upside: +710.81%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $2.13
Upside: +87.79%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $294.30
Upside: -58.21%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $73.84
Upside: -36.35%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $49.81
Upside: +118.83%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $21.73
Upside: -
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $8.06
Upside: +185.36%